With major backing from New York and China, Athenex sets sights on a $100M cancer drug IPO
Johnson Lau wants to make his comeback as CEO of a public biotech company, even though the last outing 15 years ago didn’t go so …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
